Skip to main content

Table 2 Sensitivity, specificity, and positive and negative predictive values (PPV and NPV) of the DNA methylation biomarkers (RARB, RASSF1, and GSTP1) and PSA for predicting upstaging, upgrading, and risk group increase

From: Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging

Parameter

Upstaging

Upgrading

Risk change

Sensitivity, %

Specificity, %

PPV, %

NPV, %

Sensitivity, %

Specificity, %

PPV, %

NPV, %

Sensitivity, %

Specificity, %

PPV, %

NPV, %

Voided urine (N = 188)

 PSA

86.7

27.9

23.4

89.1

82.6

27.0

29.7

80.6

85.0

27.4

26.9

85.3

RARB, RASSF1, GSTP1

52.3

72.5

32.6

85.6

50.7

67.5

36.9

78.6

45.8

71.3

33.4

80.7

RARB, RASSF1, GSTP1+PSA

56.8

65.2

29.4

85.6

47.8

74.6

41.2

79.3

89.8

27.0

27.9

89.4

RASSF1, GSTP1

50.0

73.9

32.8

85.3

50.7

69.3

35.7

78.1

45.8

71.3

33.4

80.7

RASSF1, GSTP1+PSA

54.5

66.7

27.7

84.6

40.3

81.6

45.0

78.5

89.8

27.0

27.9

89.4

Catheterized urine (N = 326)

 PSA

73.1

51.4

27.7

88.2

66.1

64.8

41.2

87.3

58.2

62.6

32.8

82.7

RARB, RASSF1, GSTP1

68.7

43.7

23.7

84.6

63.8

54.8

34.5

80.2

30.2

82.4

35.0

79.0

RARB, RASSF1, GSTP1+PSA

60.9

63.3

29.7

86.4

56,9

79,2

50.5

83.1

56.6

62.1

31.2

81.4

RASSF1, GSTP1

67.2

53.9

27.1

86.6

84.5

3.6

24.7

38.4

35.8

75.8

31.7

79.0

RASSF1, GSTP1+PSA

65.6

64.9

27.5

86.5

55.2

80.5

51.4

82.8

58.5

61.2

32.2

82.4